By using state-of-the-art genomic technologies and an unprecedented level of collaboration with the leading research institutions in New York, the NYGC is on the cutting edge of investigation into the origins, diagnosis and evolution of cancer.
Genome Center Cancer Group
The Genome Center Cancer Group (GCCG), led by Harold Varmus, MD, NYGC and Weill Cornell Medicine, and Charles Sawyers, MD, Memorial Sloan Kettering Cancer Center, is composed of clinicians and cancer researchers from NYGC’s member institutions, including 10 NCI-Designated Cancer Centers. The GCCG launched Polyethnic-1000, a project to study cancer in New York’s ethnically diverse, underserved patient populations. The group is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers. NYGC Core Faculty Members Marcin Imielinski, MD, PhD; Dan Landau, MD, PhD; and Neville Sanjana, PhD, are all also engaged in pioneering cancer research.